REVISTA DE LOS ESTUDIANTES DE MEDICINA DE LA UNIVERSIDAD INDUSTRIAL DE SANTANDER

Artículo original

Validity and reliability of autonomic symptom test

María Eugenia Niño Mantilla* César Augusto Ortiz Gualdrón** Catalina Gómez Peñaloza**

Summary

Introduction: the cardiovascular autonomic neuropathy increases the risk of silent myocardial ischemia and intraoperative cardiovascular liability. Additionally, from 27 to 56% of the patients with this diagnosis dies in the following 5-10 years. Cardiovascular autonomic neuropathy is detected by means of an electrocardiograph registration that monitors changes in heart rate induced by different stimulus. The autonomic symptom profile evaluates symptoms of autonomic function but it was not considered their reliability and validity with cardiovascular autonomic neuropathy diagnosis. It was carried out a study to determine the validity and reliability of the autonomic symptoms profile in the diagnosis of cardiovascular autonomic neuropathy. Materials and methods: from june to december of 2005, 103 participants responded the questionnaire spanish version twice. Then, 52 participants took the autonomic function test; the validity of the content of the questionnaire was evaluated by the cronbach's alpha and the reliability test-retest by intraclass correlation coefficient. It was considered the prevalence, sensibility and specificity of the score obtained with the presence of cardiovascular autonomic neuropathy. Results: The validity of content was good (cronbach's alpha >0,7). The reliability of the total score questionnaire was poor intraclass correlation coefficient (ICC 0,36 0,06-0,6) and the discriminative capacity of the questionnaire for the detection of cardiovascular autonomic neuropathy was bad for anyone of the selected court points Receiver operating curve (ROC area 0,5). Conclusions: the questionnaire evaluates the symptoms of autonomous function consistently; it has a low reliability and poor discriminative capacity to define the presence of cardiovascular autonomic neuropathy. (MÉD.UIS. 2009;22(2):149-57).

Key words: Autonomic function. Reliability. Validity. Cardiovascular autonomic function. Neuropathy. Diabetes mellitus.

*MD. MSc en Epidemiología. Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Bucaramanga. Bucaramanga, Colombia.

**Estudiantes de medicina XII nivel. Facultad de Medicina. Universidad Autónoma de Bucaramanga. Bucaramanga. Colombia.

Correspondencia: Dra. Niño. Calle 157 Nº 19-55. Cañaveral Parque. Facultad de Medicina. Campus El Bosque. Universidad Autónoma de Bucaramanga. Bucaramanga. Colombia. Teléfono: 6436111 Ext. 556. e-mail: mnino@unab.edu.co

Artículo recibido el 18 de marzo de 2009 y aceptado para publicación el 14 de agosto de 2009

NTRODUCTION

The Cardiovascular Autonomic Neuropathy (CAN) is characterized by the deterioration of small myelinized and unmyelinized autonomic fibers that innerve the heart, blood vessels and different organs in the gastrointestinal and urogenital systems¹. These complications are frequent in diabetes mellitus and the risk both silent myocardial ischemic and intraoperatory liability are higher in this population. Additionally, from 27 to 56% of diabetics with CAN dies in the following 5-10 years^{1.2}. The prevalence of CAN is from 7 to 27%, it depends on the population studied and diagnostic criteria used¹. The CAN diagnosis is made with a continuous electrocardiograph registry that detects the variability of heart rate after different stimulus (e.g. deep breathing, lying to standing). These measurements are the most useful in these people³⁻⁵. In spite of objectivity and standardized methods, the principal disadvantage is the necessity of specialized laboratory, accessibility and cost in developing countries.

The autonomic symptom profile is a questionnaire with 74 questions created previously and evaluated in face and content validity⁶. In that study, the authors showed that scores in patients with autonomic neuropathy were higher than healthy ones and patients with other neuropathies⁶. However, they did not evaluate the reliability test-retest, internal consistency and criteria validity with objectives measurements of autonomic function. It was carried out a study to determine the validity and reliability of the profile of autonomous symptoms in the CAN diagnosis.

MATERIALS AND METHODS

Participants between 15 to 65 years old, with diagnosis of diabetes mellitus, assistants to program of chronic disease in a clinical center of Bucaramanga, Colombia were selected. Participants with deafness or mental incapacity for answer the questionnaire were excluded. The protocol was approved by ethical committee of the Universidad Industrial de Santander. All patients gave their consent in order to participate in the study.

The autonomic symptom profile was translated and retro-translated from English to Spanish by two translators with good understanding of English. The authors had consensus and there was no difference in meaning or sense with the original version.

All participants had an interview with a nurse previously trained, who applied the instrument in a standardized way. The second measurement was realized in similar conditions but by telephone. The questionnaire was graded according to the author's test. The total score was 0-200 for men and 0-170 for women.

The autonomic function test was realized from 10:00 a.m to 4:00 p.m. in an isolated room with temperature approximately of 22 °C. Antihypertensive medicines or other treatment were no suspended due to the usual condition of the patients. Bv means of an electrocardiography register and used the Wincprs version.1.1597 the cardiac cycle was measured in three conditions, rest breathing, deep breathing (6 cycles/min) and lying to standing. The deep breathing was controlled by a visual timer that allow to train during a minute before the definitively register. There were obtained the 30/15 ratio, E/I ratio, delta E-I ratio, mean RR and other measurements of heart rate variability. The signal's evaluators were masked to the scores obtained in the questionnaire and the double reading. There were two readings in the autonomic function measurements. The evaluators had two years and three months of experience respectively. Cutoffs default American population data were taken for standardization by Ewing, Ziegler and Gerritsen, et al. (Table 1)^{5,8,9}.

SAMPLE SIZE

It was calculated a sample size of 102 participants to detect a prevalence of CAN about 22% with an error in the estimation of

Table	1.	Cutoffs	of	autonomic	measurements.	
Measures				Cutoffs		
E/I ratio				< 1,25*		
30/15 ratio				< 1*		
delta E/I				20-24 years <136 ms		
				25-29 years <127,4 ms		
				30-34 years	<119,4 ms	
				35-39 years 111,9 ms 40-44 years <104,8 ms		
				45-44 years < 98,2 ms		
				50-54 years <86,2 ms		
				56-60 years < 80,8 ms		
				61-65 years < 75,7 ms		

Abbreviations: *No units, ms: milliseconds

12% and alpha and beta error of 5% and 20% respectively. The study took 50 participants to apply objective autonomic test and maintained minimum 10 participants in the marginal ones the table of two by two with the prevalence estimated¹⁰. For the reliability study it was estimated a intraclass correlation coefficient between 0,6-0,8 in order to reject the null hypothesis of none agreement between both measurements. This was an alpha error 5% and power of 80%. In agreement with Kraemer¹¹ it was calculated a delta in the following form: $\Delta = (0,6-0,8)/(1-(0,6*0,8)) = 0,38$. This value was searched in the master table in the book and it was selected with the power and alpha wished (n = 41 + 1).

STATISTICAL ANALYSIS

The content validity was evaluated with cronbach's alpha and excluded items that improved or maintained the internal consistency among 0,7 to 0,9.12 The agreement was calculated with the intraclass correlation coefficient and their confidence intervals of 95%¹³. For criteria validity, the measurement of autonomic function was compared with the best reliability and cut-points publicated and the total score. Initially it was calculated the level of the test (Q), the predictive values (PPV, NPV) and confidence intervals directly for each ten points of the total score. In according with the sampling, conditional probability with Bayesian approximation was used to calculate sensibility (S), specificity (E) and prevalence (P)¹⁰. Then, a ROC curve was constructed. The statistical analysis was done in the STATA 8.014.

AUTONOMIC SYMPTOM PROFILE

The mean total score in the autonomic symptom profile was 22 points RIQ (8,75-33). The secretomotor symptoms was the highest score compared with the other dominions, mean 3 points RIQ (1,5-6); followed by the upheavals of the sleep, mean 1,5 points RIQ (0-2,3). In the sexual activity symptoms the erectile dysfunction had a high score in this group, mean 8,0 points RIQ (2-9). All participants referred some symptoms; it was found that the vasomotor symptoms were the most frequent, followed by sleep and pupil alterations. Additionally, the sub-scale that measure the presence of previously symptoms related with concentration problems, nausea, diarrhea, loss of appetite or epigastric pain was also high. Only domains of orthostatism, syncope, vasomotor symptoms, secretomotor symptoms, diarrhea, constipation and pupil alteration showed internal consistency among 0,7 to 0,9, cut points recommended to consider good internal consistency (Table 2).

RESULTS

From june to december 2005, 103 persons were included in the study. The mean age was 57 years RIQ (52-62 years), 38% were men. The majorities were diabetic type 2 (69%), received oral treatment (75%) and up to 50% has been diagnosed more than six years before stic RIQ (6-10 years) (Table 3).

RELIABILITY OF AUTONOMIC MEASURES

Reliability of autonomic symptom profile was low because almost all domains had intraclass correlation coefficient (ICC) lowers than 0,7; except the questions about erectile dysfunction ICC 0,75 (0,58-0,86). Probably these symptoms were remembered easier and with lowest variation on the time (Table 1). The measurements obtained of the autonomic function test were reliable among evaluators, the most reliable were the Pnn50 and the delta E-I ICC 0.98 (0,97-0,99) (Table 4).

CRITERIA VALIDITY

The prevalence of CAN founded in this study was 43% in the delta E-I, 28% in mean R-R and 85% in E/I ratio. The 72% of participants obtained more than 10 points in the total score (Q), there was not a cut-off point with both good specificity and sensibility and the discriminative capacity of the total score for CAN diagnosis was in the random line in spite of the measurement considered (Figure 1). The score with the better sensibility was >10 points (S= 63%) and >50 points for specificity and efficiency (E=91%; Eff= 60%). The best

Table 2. Reliability test-retest, internal consistency autonomic symptom profile.

Variable	P50 (RIQ)	% >0 (IC95%)	alpha cronbach	ICC (IC 95%)	
Total score*	22,1 (8.75-33)	100 (42-63)	0,85	0,36 (0,06-0,6)	
Orthostatic intolerance	1,3 (0-20)	52 (42-62)	0,85	0,28 (0,01-0,54)	
Syncope	0 (0-0)	12 (6-19)	0,79 ¶	0,41 (0,12-0,63)	
Vasomotor	0 (0-0)	19 (12-28)	0,79	0,46 (0,18-0,67)	
Secretomotor	3 (1,5-6,0)	99 (94-99)	0,76	0,18 (-0,12-0,46)	
Gastroparesis	0 (0.0-1,7)	32 (23-42)	0.42	0,21 (-0,09-0,49)	
Diarrhea	0 (0-0)	21 (14-30)	0,73¦	0,26 (-0,52-0,04)	
Constipation	0 (0-1,5)	39 (29-49)	0,72	0,35 (0,05-0,59)	
Slowed down vesical evacuating	0 (0,0-2,0)	39 (29-49)	0,49	0,23 (-0,07-0,5)	
Pupillomotor reflex alterations	0,5 (0,0-1,5)	65 (55-74)	0,73	0,51 (0,24-0,7)	
Sleep	1,5 (0,0-2,3)	75 (65-83)	0,23	0,17 (-0,14-0,45)	
Eréctil dysfunction †	8 (2-9)	27 (19-37)	0,67	0,75 (0,58-0,86)	
Ejaculation problems †	0 (0-0)	5 (2-10)	0,63	-0.1 (-0,1-0,39)	
Validity scale					
Psychosomatic	0 (0,0-0,0)	11 (5-18)	0,52	0 (-0,3-30)	
Understatement index	8,3 (4,9-8,3)	98 (93-99)	0,67	0,15 (-0,15-0,44)	

Abbreviations: % > 0 = Percent of people with scores higher than cero. *Total score: men 0-200; women 0-170. † Only men. ‡ Only questions 10 y 11. ¶ excluded question 47.

(PPV) in the cut off > 20 points was for E/I ratio (Table 5).

DISCUSSION

The dysfunction of the autonomic nervous system is a serious problem in diabetic patients. The cardiovascular autonomic neuropathy is the most important autonomic dysfunction for it's implication in the increase of mortality rate², therefore the importance of detecting and quantifying the symptoms of autonomic dysfunction. The patients with CAN present episodes of silent myocardial ischemia that can evolve easily into a myocardial infarction¹⁵⁻¹⁷, also presents intraoperative cardiovascular lability representing morbidity and mortality two to three times higher compared to nondiabetics¹⁸. Burgos and Cols. showed that the induction of anesthesia caused a large decline in heart rate and blood pressure in these patients, and the administration of vasopressors is most frequently used¹⁹, Kitamura and Cols. found an association between severe intraoperative hypothermia and CAN, which would generate a decrease in the metabolism of the drug and problems in the healing of the wound²⁰ and Sobotka and Cols. showed that

diabetic patients with CAN have reduced the hypoxic ventilatory response induced²¹. Therefore, the investigation of CAN in all diabetics to be subjected to surgery is essential to identify patients at risk, and plan carefully anesthetic treatment for the patient.

Being important the recognition of autonomic symptoms, Suarez and cols. describe a questionnaire (Autonomic symptom profile) that measures a wide range of symptoms related to different aspects of autonomic disorders in grouping domains that provide a scoring system called the Composite Autonomic Symptom Scale (COMPASS)². The questionnaire has an internal validity demonstrated to compare the results with the Symptom Composite Autonomic Scoring Scale (CASS)²², derived from a group of non-invasive tests sensitive, specific, reproducible and standardized that detect and quantify symptoms of autonomic dysfunction, having a good correlation (p < 0,001).

In the present study, the psychometric characteristics of autonomic symptom profile were analyzed since different aspects such as reliability, internal consistency and criteria

Characteristics	Participants N=103		
Demographic			
Age years, p50 (RIQ)	57 (52-62)		
Gender, (male) n (%)	39 (38)		
Socio-economic level			
Low 0-2, n (%)	46 (45)		
Middle / high 3-6, n (%)	56 (55)		
Diabetes mellitus			
Type 1, n (%)	20 (19)		
Type 2, n (%)	71 (69)		
Non Classify, n (%)	12 (12)		
Diagnostic time years, p50 (RIQ)	6 (6-10)		
Fasting glucose mg/dl, p50 (RIQ)	141 (113-180)		
Treatment			
Insulin, n (%)	23 (22)		
Oral medicines, n (%)	76 (74)		
Exclusive diet / nothing, n (%)	4 (4)		
Comorbidities			
Hypertension, n (%)	40 (39)		
Antecedent of high cholesterol, n (%)	31 (30)		
Antecedent of low thyroid hormone, n (%)	4 (4)		
Previous stroke, n(%)	1 (1)		
Previous myocardial infarction, n(%)	1 (1)		
None, n (%)	26 (25)		
Physical exam			
Weight kg, mean (SD)	69 (13.0)		
Height mts., mean (SD)	1.6 (0.08)		
Body mass index, mean (SD)	27 (4.37)		
Cardiac pulse, mean (SD)	73 (10)		
Systolic blood pressure (mmHG), mean (SD)	119 (14)		

Abbreviations: p50: percentile 50, p25: percentile 25, p75: percentile 75, (SD): standard deviation.

validity in front of objectives measurements of autonomic cardiovascular function.

The tests were evaluated in diabetic people with a long term evolution of the disease in whom the CAN have high prevalence and the performance of the test could be best way of diagnose the condition¹⁰. However, it could not be demonstrated that the presence of autonomic disease is related with the presence of autonomic symptoms. This results are explained by the chronic condition of the disease, since in other methodological reports have been detected problems to apply questionnaires in patients with this type of diseases¹². This participants can overestimate or underestimate their symptoms and to lose the discriminative capacity of the instrument¹².

In previous studies the autonomic symptoms were evaluated using other standardized instruments that ask about the frequency of symptoms in the last 30 days. The Diabetes control and complications trial (DCCT study (diabetic 26 to 34 years), used this type of instrument and the most frequent symptom was postural hypotension (3,9%) followed by hypoglycemic unadvertised (8,7%)²³. Ziegler and Cols. found postural dizziness (11%) and erectile dysfunction as more frequent (19%)²⁴. It was founded the erectile dysfunction with the highest score (8 points).

Low and Cols. applied the autonomic symptom profile in a study and the results were similar than the obtained in this study. For example, the vasomotor symptoms they found mean 0,98 points (SD=1,98) and in the evaluated people the mean was 0,86 (SD=2)²⁵. However, this shows the necessity to modify the scale, because it probably does not reflect the state of the patients.

In the other side, the reliability of the autonomic symptoms was poor showing the variability of its occurrence. This situation reduces the reliability of the measurement and induces a misclassification. In epidemiological research it is recognized that a no reliable instrument reduces the discriminative capacity and increase a sample size of the studies²⁶.

The measurements of objective autonomic measures were a good reliability among two evaluators, independent of their experience. This guarantees the precision of measures for diagnosis in CAN but do not guarantee the presence of the disease. This was not a scope of this study because the evaluation of real autonomic function does not have a gold standard. However, it is accepted with expert consensus that the autonomic function must be evaluated with the Ewing tests. The experts

Factor	Evaluator 1 Mean (SD)	Evaluator 2 Mean (SD)	ICC (IC 95%)
Mean R-R, ms	788 (95,3)	791 (91,3)	0,97 (0,95 – 0,98)
Ratio 30/15	1,07 (0,10)	1,08 (0,13)	0,63 (0,42 – 0,77)
Ratio E/I	1,15 (0,01)	1,16 (0,01)	0,97 (0,95 – 0,98)
Delta E-I, ms	118 (66,4)	122 (69,9)	0,98 (0,97 – 0,99)
Minimum, ms	707 (79,5)	711 (98,3)	0,71 (0,55 – 0,83)
Maximum, ms	880 (119)	864 (107)	0,91 (0,85 – 0,94)
CV	2,3 (1,07)	2,2 (1,19)	0,89 (0,83 – 0,94)
RMSSD	18 (9,9)	18 (11)	0,92 (0,86 – 0,95)
Pnn 50, ms	2,8 (6,21)	2,8 (6,73)	0,98 (0,97 – 0,99)

Table 4. Reliability of measures of autonomic function test.

Abbreviations: Mean R-R: Mean of R-R intervals, Ratio 30/15, E/I: Expiration /Inspiration ratio. Delta E-I: differences of the intervals R-R in Expiration and inspiration, Minimum: Mean of R-R intervals minimum. Maximum: Mean of R-R intervals maximum. CV: Variation coefficient, RMSSD: The sum of squares of mean differences squares among R-R intervals. Pnn 50: Percent of R-R intervals that differ more than 50 ms. Ms: milliseconds.

recommend at first line the delta E-I in diabetic people⁴.

The criteria validity of autonomic symptom profile was analyzed with a prospective sample, this had an advantage in saving money and time because it wasn't needed to do the objective measures in all sample. This methodology is a simple application of Bayesian theory used in evaluating medical test. Confidence intervals for prevalence, sensibility and specificity weren't calculated because they did not found directly unlike the predictive values¹⁰.

The autonomic symptom profiles does not only evaluate cardiovascular symptoms and one of the limitations is doing measurements of autonomic function in other organs. However, the study was interested in evaluate autonomic symptom profile in the detection of CAN mainly. In the other side, it's shown how a reliability of the measures between evaluators is enough for use in clinical practice and research. Additionally, autonomic symptom profile could be modified with questions about of acute autonomic symptoms related with diseases like sepsis or Systemic Inflammatory Response Syndrome (SIRS) where autonomic system is a modulator in cardiovascular answer mediated by endotoxin²⁷.

The results of this study does not assign to a systematic bias in patients selection because

these were included in a consecutive and the performance of autonomic measures was masking of the score of autonomic symptom profile. The patients with measurements without interpretation were not excluded¹¹.

In clinical practice, this questionnaire can be used to identify diabetic patients with autonomic neuropathy and also to diagnose the disease early to treat diabetes more intensively because only the approach and maintenance of near glucose blood levels are the most effective way to prevent the cardiovascular autonomic neuropathy in the diabetic patients^{23,28,29}.

CONCLUSION

The autonomic symptom profile has a good internal consistency, poor reliability testretest and did not have a discriminative capacity for the diagnosis of autonomic cardiovascular function. The test identifies diabetic patients who have symptoms of cardiovascular autonomic neuropathy of those who do not have. This is important in clinical practice for its implication in the increase of the mortality rate, allowing the selection of diabetic patients in which diabetes should be treated more intensively. Another important feature of the test is the potential ability to recognize clinically important changes, such as improvement or worsening of symptoms, MAYO-AGOSTO



Figure 1. Area under the curve of total score and three measures of autonomic function.

A= delta E-I; B= mean R-R; C= E/I ratio.

which may translate into scores useful to monitor the progression of disease and to evaluate the response to treatment but further testing is needed to assess it. Our new research proposal is to establish the frequency of the autonomic neuropathy symptoms and evaluate their association with the duration of diabetes and socioeconomic and therapeutic variables, because this information is unknown in the colombian and latin-american population. It's also interesting the investigation of the presence of acute autonomic symptoms related with sepsis or SIRS, since the topic has not been explored so far.

ACKNOWLEDGEMENTS

Thanks to Dr. Juan Carlos Villar Centeno and the Grupo de Cardiología Preventiva de la Universidad Autónoma de Bucaramanga by their contribution in autonomic function test. Dra. Sandra Milena Quiroga, Dr. Gabriel Torres, Dr. Adalberto Campo Arias and Dr. Luis Alfonso Díaz Martínez for their support in different steps of the process.

RESUMEN

Validez y confiabilidad de la prueba de síntomas autonómicos. Introducción: la neuropatía autonómica cardiovascular incrementa el riesgo de isquemia miocárdica silente y de inestabilidad cardiovascular intraoperatoria. Además, el 27 al 56% de los pacientes con este diagnóstico muere en los siguientes 5 - 10 años. La neuropatía autonómica cardiovascular es detectada por medio de un registro electrocardiográfico que monitorea cambios en la frecuencia cardíaca inducida por diferentes estímulos. El perfil de síntomas autonómicos es un test que evalúa síntomas de función autonómica pero no se ha considerado su confiabilidad y validez con el diagnóstico de neuropatía autonómica cardiovascular. Se realizó un estudio para determinar la validez y confiabilidad del test de perfil de síntomas autonómicos en el diagnóstico de la neuropatía autonómica cardiovascular. Materiales y métodos: de junio a

Table 5. Validity criteria of autonomic symptom profile and autonomic function test.

Autonomic	Delta E/I		Mean R-R		E/I ratio	
profile	Positive	Negative	Positive	Negative	Positive	Negative
> 20	11	12	6	16	20	2
< 20	10	17	8	20	22	6
Total	21	29	14	36	42	8
P (%)	43		28		85	
Q (%)	53 (43-63)		53 (43-63)		53 (43-63)	
S (%)	59		52		56	
E (%)	51		47		56	
PPV (%)	44 (31-57)		25 (16-41)		84 (74-94)	
NPV (%) 63 (49-67)		70 (57-84)		22 (10-34)		

Abbreviations: Mean R-R: Mean of R-R intervals, Ratio 30/15, E/I: Expiration/Inspiration ratio. P: Prevalence; Q: level of the test; S: sensibility; E: Specificity; PPV: positive predictive value; NPV: negative predictive value; CI 95%: confidence interval 95%.

NIÑO M, ORTIZ C, GÓMEZ C

diciembre de 2005, 103 participantes respondieron la versión en español del cuestionario de perfil de síntomas autonómicos en dos oportunidades. Después, 52 participantes tomaron la prueba de función autonómica, la validez del contenido de cuestionario fue evaluada por medio del alfa de cronbach y la confiabilidad test-retest por medio del coeficiente de correlación intraclase. Se consideró la prevalencia, sensibilidad y especificidad del puntaje obtenido con la presencia de neuropatía autonómica cardiovascular. Resultados: la validez del contenido fue buena (alfa de cronbach >0,7). La confiabilidad del resultado total del cuestionario fue pobre coeficiente de correlación intraclase (ICC 0,36 0,06-0,6) y la capacidad discriminativa del cuestionario para la detección de neuropatía autonómica cardiovascular fue mala para cualquiera de los puntos de corte seleccionados (Área ROC 0.5). Conclusiones: el cuestionario evalúa los síntomas de función autonómica sistemáticamente; tiene una baja

confiabilidad y pobre capacidad discriminativa para definir la presencia de síntomas de neuropatía autonómica cardiovascular. (MED.UIS. 2009;22(2):146-54). Palabras clave: Función autonómica. Confiabilidad. Validez.

Función autonómica cardiovascular. Neuropatía. Diabetes mellitus.

BIBLIOGRAPHIC REFERENCES

- Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553-79.
- Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: Metanalysis. Diabetes Care 2003; 16: 1895-901.
- Hohnloser SH, Klingenheben T. Basic Autonomic test. In: Malik M, eds. Clinical Guide to cardiac autonomic test. London: Kluwer Academic Publishers, 1998. p. 51-66.
- American diabetes association and American academy of neurology. Consensus statement: report and recommendations of the San Antonio Conference on Diabetic Neuropathy. Diabetes Care 1988; 11: 592-7.
- Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985; 8: 491-8.
- Suarez GA, Opfer-Gehrking TL, Offord KP, Atkinson EJ, O'Brien PC, Low PA. The autonomic symptom profile. A new instrument to assess autonomic symptoms. Neurology 1999; 52: 523-8.
- WinCPRS vers.1.159 (CardioPulmonary Research Software for Windows) has been classified as a Medical Device to the class IIa according the Medical Device Directive (MDD) 93/42/EEC.ISO 13485.

- Ziegler D, Laux G, Dannehl K, Spüler M, Mülen H, Mayer P. Assessment of cardiovascular autonomic function: age related normal ranges and reproducibility of spectral analysis, vector analysis and standard tests of heart rate variation and blood pressure responses. Diabet med 1992; 9: 166-75.
- Gerritsen J, Ten Voorde B, Dekker J. Measures of cardiovascular autonomic nervous function: agreement, reproducibility, and reference values in middle age and elderly subjects. Diabetología 2003; 46: 330-8.
- Kraemer HC. Evaluating Medical test. In: Kraemer HC ed. Objective and quantitative guidelines. First edition. Newbury: Sage Publications; 1992.
- Kraemer HC, Thiemann S. Correlation coefficients. In: Kraemer HC ed. How many subjects?. First. edition. Newbury: Sage Publications. 1987. p. 54-5.
- Streiner DL, Norman GR. Health Measurement scales. In: A practical guide to their development and use. Second edition. New York: Oxford University Press Inc. 1995.
- Bartko JJ. On various intraclass correlation reliability coefficients. Psychological metrics 1976; 83: 762-5.
- 14. Stata Statistical Software: release 8.0. College Station: Stata Corporation; 2003.
- 15. Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004; 27: 1954-61.
- 16. Valensi P, Sachs RN, Harfouche B, Lormeau B, Paries J, Cosson E, et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001; 24: 339-43.
- 17. Shakespeare CF, Katritsis D, Crowther A, Cooper IC, Coltart JD, Webb-Peploe MW. Differences in autonomic nerve function in patients with silent and symptomatic myocardial ischaemia. Br Heart J 1994; 71: 22-9.
- Milaskiewicz RM, Hall GM. Diabetes and anaesthesia: the past decade. Br J Anaesth 1992; 68: 198-206.
- 19. Burgos LG, Ebert TJ, Asiddao C, Turner LA, Pattison CZ, Wang-Cheng R, et al. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. Anesthesiology 1989; 70: 591-7.
- 20. Kitamura A, Hoshino T, Kon T, Ogawa R. Patients with diabetic neuropathy are at risk of a greater intraoperative reduction in core temperature. Anesthesiology 2000; 92: 1311-8.
- Sobotka PA, Liss HP, Vinik AI. Impaired hypoxic ventilatory drive in diabetic patients with autonomic neuropathy. J Clin Endocrinol Metab 1986; 62: 658-63.

MÉD. UIS. 2009;22:149-57

MAYO-AGOSTO

- Low PA. Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. Mayo Clin Proc 1993; 68: 748-52.
- 23. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998; 41: 416-23.
- 24. Ziegler D, Laux G, Dannehl K, Spüler M, Mülen H, Mayer P. Assessment of cardiovascular autonomic function: age related normal ranges and reproducibility of spectral analysis, vector analysis and standard tests of heart rate variation and blood pressure responses. Diabet med 1992; 9: 166-75.
- 25. Low PA, Benrud-Larson LM, Sletten DM, Opfer-Gehrking TL, Weigand SD, O'Brien PC, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 2004;27:2942-7.

- 26. Fleiss JL. Reliability of measurement. In: Fleiss JL. The design and analysis of clinical experiments. First edition. New York. 1986. p. 1-32.
- 27. Werdan K, Schmidt H, Ebelt H Impaired regulation of cardiac function in sepsis, SIRS, and MODS. Can J Physiol Pharmacol. 2009;87(4):266-74
- 28. Larsen JR, Sjoholm H, Berg TJ, Sandvik L, Brekke M, Hanssen KF, et al. Eighteen years of fair glycemic control preserves cardiac autonomic function in type 1 diabetes. Diabetes Care 2004; 27:963-6.
- 29. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.